The levels of serum FGF-23, a biomarker of phosphorus metabolism during CKD, markedly increased in the IRI-induced CKD mice, which could also be reversed by LIPUS treatment (Figure 2C). The gene discussed is FGF23; the disease is chronic kidney disease.